Acta Scientific Neurology (ISSN: 2582-1121)

Volume 5 Issue 6 June 2022

Review Article

Deep Brain Stimulation: A Provocative Pathways and Neuroprotection - The Focus of Efforts Aimed at Slowing the Progression of Parkinson's Disease - Part I

V Rama Raju*

Professor of Computer Science and Engineering, Computational Neuroscience, and Cognitive System, CMR College of Engineering and Technology (UGC Autonomous), Kandlakoya (V), Medchal Rd., Hyderabad, Telangana, India

***Corresponding Author:** V Rama Raju, Professor of Computer Science and Engineering, Computational Neuroscience, and Cognitive System, CMR College of Engineering and Technology (UGC Autonomous), Kandlakoya (V), Medchal Rd., Hyderabad, Telangana, India

DOI: 10.31080/ASNE.2021.05.0504

Received: March 18, 2022

Published: May 03, 2022

Abstract

Development of neuro protection has turn out to be the focal point of endeavors targeted at reducing the progress of Parkinson disease or Parkinson`s disease (PD) signs and symptoms which are fundamental feature manifestations characterized by the four classes of motoric (motor) symptoms of PD, namely tremor, Bradykinesia (akinesia), postural instability and rigidity. One of the most common neurologic disorders that elders experience, Parkinson disease is a dreadful diagnosis impacting nearly - circa ~2of every 00 adult-subjects more than 60 years old older-adults. Even though there is presently no-cure as well as existing PD-treatments improve relieve only the motor-symptoms rather than the disease's progression, therefore, a bright possibility lies in latest research experimental investigational studies concentrating upon the neuro protection. This article study the provocative pathways that lead to the development of deep brain stimulation of the subthalamic nucleus, a surgical procedural method (with which an innocuous microelectrode is implanted into the region of substantia nigra) which reduces Parkinson tremors and restores motor-function in patients with advanced idiopathic Parkinson's disease. PD, the causes of which are not known, is a chronic, progressive brain disorder that belongs to a larger class of disorders called movement disorders. In PD, one population of brain cells-those that produce a chemical messenger called dopamine-become impaired and are lost over time. The loss of these brain cells causes circuits in the brain to function abnormally, and those abnormal circuits result in movement problems.

Keywords: Deep Brain; Provocative; Neuroprotection; Parkinson's Disease

Introduction

Human brain is a dynamic organ. Even though it is naturally and highly structured but is very complex and indeed nebulous tissue. Incredibly it is a complex network circuit approximately circa ~ 10^{100} cells possibly deal some tiny blips in the system. It is continuously adapting and changing in response to changes in the internal and external environments. Mysteries of the brain is untying record pace or tempo. Scientists are mapping and implanting coordinates in brain. To identify area that controls various body's function then scientists targets these coordinates when treating and conducting Parkinson`s disease or Parkinson disease and movement disorders research.

In the year 2014, the Lasker ~ De Bakey Clinical Medical Research Award honored two renowned neuroscientists who has

developed deep brain stimulation of the subthalamic nucleus, a minimally invasive surgical-technique that reduces tremors and restores motor function in patients with advanced idiopathic Parkinson's or Parkinson disease (PD) [1-8]. "For the development of deep brain stimulation of the subthalamic nucleus, a surgical technique that reduces tremors and restores motor function in patients with advanced Parkinson's disease" [9].

Mahlon R. DeLong (Emory University School of Medicine) formulated a new model for the brain's circuitry and exposed a fresh target for this illness. Alim Louis Benabid (Joseph Fourier University, Grenoble) devised an effective and reversible intervention that remedies neuronic (neuronal/or) neural misfiring's. Globally, till date (as on to date), this Darlington pair duos effort has concluded/or-culminated in a successful and most efficient therapeutic-treatment for over 200,000 individuals worldwide through critical ill health (disease) who suffer from hitches of levodopa (L-dopa) therapy.

L-dopa is a dopamine precursor applied in the medical management of Parkinson disease, often in blend in conjunction with carbidopa, along with other circumstances, settings and situations associated through parkinsonism. Carbidopa/levodopa, also known as levocarb and co-careldopa, is the pattern sequence of the two drugs, i.e., medicines(medications) carbidopa and levodopa which is primely used to control or manage the signs and symptoms (which are referred to as feature manifestations) of the Parkinson's disease. However, with this medication, the disease progression getting worse and patients suffering with various dyskinesias (side effects) with non-motoric symptoms such as memory problems like cognitive dementia, cognitive impairment, hallucinations, slurred speech and followed by the various axial symptoms. It is taken by mouth.

Parkinson's disease is the second most common neurodenerative disease that is exemplified by the convolution of four classes of cardinal motor symptoms, namely, tremor, rigidity, bradykinesia and postural instability. The search for optimal cure is on for the past 2 centuries since the time it was first described by James Parkinson [1].

Parkinson's disease identified and possibly well-known for its tremor [10]. Since the 1940s all the way through the 1960s, surgeons struggled the ailment by obliterating areas of the brain, chosen more by heuristics-based trial and error methods than by a clear understanding of neuronal neuronic misbehavior (nervousness) [11]. The so-called lacerations or wounds termed as lesions created by these surgical operations frequently delivered incredible and/or magnificent spectacular and dyskinesias (stable effects), neutralizing (or counteracting) tremor and, to some extent and in some measure to a degree, additional feature-manifestations of Parkinson`s. Even an iota of slight and insignificant malposition (misplacement), though, brought complications rather than benefits. Such damage was constantly-enduring, perpetual, and everlasting (permanent), as deceased soft tissue couldn't be recovered or restored [12-15].

The 1960s broke open a modern therapeutic treatment for PD following that essentially spurned scorned, (i.e., disdained, or despised) the invasive medical-surgical era. Scientists established that the malady arises from insufficient quantities of the neurotransmitter dopamine in an area of the brain that controls movement, the basal ganglia (a parallelly connected circuitry). By the end of the decade, the late George Cotzias (Lasker Clinical Medical Research Award, 1969) had stated spectacular enhancements and progressions in PD diseased patients who received and had a meticulously and wisely tuned regimen of oral L-dopa, the metabolic precursor of dopamine (c chemical messenger). The medication honeymoon, however, can wear off [1-9]. Following the long-term medical administration/ management, the drug induces severe involuntary movements in some individuals [10]. Only small windows of the day remain in which patients experience neither PD symptoms nor these disturbing effects [11-19].

Figure 1

Figure2

Provocative pathways

As MeLon R DeLong began his research, in the late 1960s, the basal ganglia had been implicated in movement, specifically for the reason that defects and deficiencies there were correlated in conjunction with diseases, illnesses, maladies, infections such as PD in which motor disturbances or turbulence's feature conspicuously and fragrantly. Little was known, nonetheless, about how exactly the basal ganglia contribute to movement and control [20-22]. To find out, Mahlon implanted innocuous-microelectrodes into primate-animal-monkeys' brains and measured the activity of certain (specific) neurons in the BG during which the primate-monkeys performed trained actions. Thus, he matched neurons with some-tasks; some influenced, for instance, the direction, size, or speed of animal arm, followed by leg, or facial expressions and movements. In this manner, in this way, he mapped out the organization of the establishment of the so-called motor-circuit [23]. Based on his own work and that of others as well as existing anatomical-structural, data, evidence, and information, Mahlon aimed a model-prototype in which basal-ganglion-neurons operate, manage and control in distinct-circuits. Numerous pathways stem from different centers in the cerebral-cortex, run all the way through and through the BG, plus gale/wind-up towards the back from which they began; the circuitry (all parallel-circuits) exertion and function together with(alongside) one alternative or another in addition let parallel processing of emotions, perceptions, thoughts, and motor functions [24].

This work was presented insights-intuitions and perceptions into the deep-rooted/well-established study that cognitive and emotional problems (cognitive impairment, cognitive dementia, etc.) come with, be associated with, and accompany several indeed many motor disorders that stem from BG failings [25]. Furthermore, the findings provided a new framework for exploring how basal ganglia components malfunction in various illnesses, including Parkinson disease. Even though the dopamine-chemical-messenger failure or injury obviously causes the disease's motor agitations, distresses, disquiets (perturbations), the linked or related and accompanying variations in BG activities were ambiguous and uncertain. Mahlon's model-which was incorporated a comprehensive and meticulous map of stimulatory and inhibitory neuronal-signals/neural-waveforms all through the BG-suggested ideas and concepts. For instance, the ultimate stop in the motor-circuit of the BG is a structure that sends confining and/or restraining orders onward, thereby suppressing other parts of the motor system. Anything that causes superfluous activity at that site might generate the symptoms that characterize PD [26].

From addicts to insights

In the early 1980s, sporadic outbreaks of a syndrome that mimics Parkinson's disease started occurring among drug addicts, and scientists traced it to a chemical, MPTP, that was contaminating some batches of "synthetic heroin." Administration of the compound to monkeys reproduced the key clinical and pathological features of PD, and thus offered a powerful new tool for studying the ailment/disease [27].

Mahlon confiscated(seized) upon the chance. An element of the BG is termed as the subthalamic nucleus (STN) drives the inhibitory output signal/waveform, and in 1987, he demonstrated, described and testified that MPTP triggers neurons in the STN of primate-monkeys to fire overly. Maybe, Mahlong reasoned, the overexuberant signals quash motor activity in PD. If so, inactivating the STN might ameliorate some of the illness's worst symptoms [28].

Next, he did an experiment that would transform PD treatment. He administered MPTP to two primate-monkeys; as usual, they gradually slowed down until they sat motionless, their muscles stiffened, and they developed tremors and then Mahlon instilled a second noxious-toxic chemical-substance that inactivated the STN. Within a minute or so, the primates begun to move about and turn about. Gradually, their muscles loosened and the tremors ceased. These findings strongly supported the hypothesis that hyperactivity in the subthalamic nucleus underlies PD symptoms [43].

High frequency, high hopes

Throughout the Atlantic, Benabid had also been tackling neurological disorders, and he was annoyed, infuriated, and discouraged. In a throwback to the pre-L-dopa era, the trickiest patients-those who did poorly with long-term pharmaceutical/pharmacological medication, therapy-would wind up in the operating room. Louis craved and yearned for a new tool-and also ne utility somewhat safer that would tranquil the highly incapacitating disabling feature-symptoms of PD [29-33].

In 1987, one day he was about to make a lesion in a person with essential-tremor, a condition that causes trembling in various parts of the his body. He was targeting an element of the thalamus that causes and gives to tremors. Characteristically, the subject was awake so Louis could test whether he had positioned the correct-tissue; he embedded a probe into the spot that he planned to gash and sent an electrical-current voltage amplitude pulse to guarantee that perturbing this site did not generate un-desired things [33-36].

Normally he delivered a 50Hertz frequency, but then he chose to find out what would happen if he expanded the frequency. Really below the frequency of 100Hertz, and then to some degree something surprised and unanticipated transpired: The shaking hand tremor ended/stopped. The subject became so still, Louis thought that he had caused unintended/unintentional involuntary-muscle spasm. He switched-off the stimuli and expressed regrets for the fault. The subject requested the Louis him not to express regrets, as it was the first time in several indeed many years that his hand had not shaken [31,43]. And he reiterated the same procedure, and same corresponding effect. Furthermore, when he left the current voltage, the tremor persisted. And thus, the results were reversible. Hence, the Louis devised an effective and reversible intervention that remedies neuronic (neuronal/or) neural misfiring's was proved.

So, he accomplished and understood that he was onto somewhat and something exhilarating. Deep brain stimulation had been used for more than two and half decades to treat agony, distress and pain, however no one had dialed up the frequency [43]. Soon after that year, he sought the same approach with the same methodology for Parkinson`s. In addition, he implanted a device that was on the market for the distress and pain-relief and delivers constant-stimulus-intensity. Several of the individuals got benefited from the procedure, and also there were no impediments occurred [32].

And in 1991, he reported that induced high-frequency stimuli could be implemented bilaterally (i.e., to the Parkinson diseased left hemisphere and to the right hemisphere) in people with essential tremor and Parkinson`s; this method/strategy lowered the tremor on two sides of the body. The gains were enduring, and undesirable adverse-side-effects were also mild/ and moderate; likewise, any unsought outcomes could be changed, overturned, and reversed by reducing the stimulus-intensity and amplitude levels [36-38].

Although the technique quelled tremors, Louis knew that this indication/symptom was not the one that extremely incapacitated people with PD. Conceivably high-frequency stimulation (induced) of brain areas other than the thalamus, i.e., the subthalamic-nucleus/STN, would alleviate the more troublesome aspects of the illness such as slowness of movement and rigidity, he reasoned [39].

In this state of mind, Louis read Mahlon's information that damage to the subthalamic nucleus wipes out multiple symptoms of PD in primate-animals, such as monkeys and gorillas. This site was not an alluring-target: Lesioning procedures and spontaneous lesions had instituted proved and then established decades earlier that, when things went wrong, violent flailing could result. Louis, however, by that time had achieved high-frequency deep brain stimulation of the thalamus and other areas of the brain regions' in over 160 subjects (patients). He was confident and convinced that he would cause no harm in the subthalamic-nucleus/STN element; and if crucial, he could get rid of the implanted microelectrode [40].

In the year 1995, Louis demonstrated the findings from the first humans who received bilateral, high-frequency DBS of the subthalamic-nucleus/STN-three subjects together with serious Parkinson`s. The therapeutic-method inhibited the slowness of the movement and muscle cramps, spasms and rigidity.

Few years later circa 2002, he validated and prolonged these findings in a study of individuals who had undergone/underwent the DB procedure prior-to-five-years. The surgical procedure, the i.e., the DBS therapeutic treatment restored motor functioning and motor-skills, inhibited the tremor, as well as advanced the capability to conduct to perform regular and routine activities of

daily-livings. Furthermore, people were able to slash their dosage of L-dopa and related medications, which reduced the dyskinesias (associated-complications) [41].

In the year 2002, the American Food and Drug Administration (FDA) authorized the high-frequency deep brain stimulation of the subthalamic nucleus (STN-DBS) for treating advanced idiopathic Parkinson's disease. The method is not a cure, and it does not reverse all aspects of the malady. Particularly, speech, cognition, dementia continue to decline [42].

Many questions remain about the mechanism of this interventional study, i.e., STN, DBS. It might jam or replace inappropriate circuit activity. Regardless how it works, surgeons are using high-frequency deep brain stimulation to combat an ever-growing number of sites and diseases: essential tremor, dystonia-a condition of involuntary muscle contractions-and even psychiatric illnesses. The FDA approved its use for obsessive-compulsive disorder (in 2009), and scientists are investigating applications for drug-resistant depression, Tourette Syndrome, Huntington disease, etc.

Through their open-minded explorations and willingness to challenge dogma, Louis and Mahlon have had delivered extraordinary medical innovations to humankind. By reaching deep into the brain, they have soothed some of the most troubling conditions that corrupt it.

Conclusion

The concept of the subthalamic nucleus deep brain stimulation and provocative thought processes has discussed in this study. In our next study as a part II, we will be demonstrating the neuroprotection the focus of efforts aimed at slowing the progression of Parkinson's disease. However, bot the studies are based on the open loop deep brain stimulation devices.

Bibliography

1. Venkateshwarla Rama Raju., *et al*. "Effect of Microelectrode Recording in Accurate Targeting STN with High Frequency DBS in Parkinson Disease". *IETE Journal of Research* (2019).

2. Venkateshwarla Rama Raju., *et al*. "Adaptive Closed-Loop Deep Brain Stimulator Coding Techniques for Target Detections in Parkinson's". *IETE Journal of Research* (2021).

3. Dabbeta Anji Reddy., *et al*. "Deep Brain Stimulation Coding in Parkinson's: An Evolving Approach". *IETE Journal of Research* (2021).

4. V Rama Raju. "A Clinico-Statistical Analysis of Writer's Cramp Signals: Study with Indigenously Developed Multi-Channel Intramuscular EMG". *IFMBE Proceedings* (2019).

5. Raju., et al. "Principal Component Latent Variate Factorial Analysis of MER Signals of STN-DBS in Parkinson's Disease (Electrode Implantation)". *IFMBE Proceedings* (2018).

6. Venkateshwarla Rama Raju. "The Probablistic Random Forest Clinico-Statistical Regression Analysis of MER Signals with STN-DBS and Enhancement of UPDRS Published". *IFMBE Proceedings* (2019).

7. Venkateshwarla Rama Raju. "Latent Variate Factorial Principal Component Analysis of Microelectrode Recording of Subthalamic Nuclei Neural Signals with Deep Brain Stimulator in Parkinson Disease". *Springer Briefs in Applied Sciences and Technology* (2019).

8. V Rama Raju., *et al*. "Microrecording of Writer's Cramp Signals with Indigenously Developed Advanced Real-Time Multi-Channel Intelligent-EMG-System". *Proceedings of the Intelligent Systems Conference (Intellisys)* Published (2017).

9. V Rama Raju. "The Role of Microelectrode Recording (MER) in STN DBS Electrode Implantation (2015).

10. Rama Raju V. "Design and Development of Advanced Multichannel EMG Micro Electrode Recording System". In: Lhotska L., Sukupova L., Lacković I., Ibbott G. (eds) World Congress on Medical Physics and Biomedical Engineering 2018". *IFMBE Proceedings* 68.2 (2019).

11. V Rama Raju. "Stimulations to Basal Ganglia and the Efficiency of Microminiaturized Electrode Recording (MER) to Quantify STN Neurons with Deep Brain Stimulator (DBS)- the Lead Point in Parkinson Diseased Conditions (2015).

12. V Rama Raju. "Mirror Movements in Writer's Cramp-A Study with Multi-Channel EMG (2013).

13. V Rama Raju. "EMG-EMG Coherence in Multisite Writer's Cramp Waveforms - A Study with Advanced Multi-Channel EMG System (2015).

14. V Rama Raju. "Mirror Movements in Writer's Cramp - Study with Advanced Real-Time Multi-Channel EMG (A Clinico-Statistical Analysis) (2015).

15. V Rama Raju. "The Role of Microelectrode Recording (MER) in STN DBS Electrode Implantation.

16. V Rama Raju. "Latent variate factorial principal component analysis of microelectrode recording of subthalamic nuclei neural signals with deep brain stimulator in Parkinson disease.

17. V Rama Raju. "Effectiveness of Lead Point with Microrecording for Determining STN-DBS in Parkinson disease using HM-Models". *IRJET- International Research Journal of Engineering and Technology (IRJET)* (2019).

18. R Jankovic J. "Parkinson's disease: clinical features and diagnosis". *Journal of Neurology, Neurosurgery, and Psychiatry* 79 (2008): 368-376.

19. Fahn S and Elton RL. "The Unified Parkinsons Disease Rating Scale. Recent developments in Parkinsons disease. Florham Park, N.J: Macmillan Healthcare Information (1987): 153-63.

20. Antoniades CA and Barker RA. "The search for biomarkers in Parkinsons disease: a critical review". *Expert Reviews* 8.12 (2008): 1841-1852.

21. Morgan JC., *et al*. "Biomarkers in Parkinsons disease". *Current Neurology and Neuroscience Reports* 10 (2010): 423-430.

22. Evelyn Strauss., *et al*. "Lasker~DeBakey Clinical Medical Research Award to Alim Louis Benabid and Mahlon DeLong (2014): 1-4.

23. Amirnovin R., *et al*. "Experience with microelectrode guided subthalamic nucleus deep brain stimulation". *Neurosurgery* 58.1 (2006): ONS96-102.

24. Kyriaki Kostoglou. "Classification and Prediction of Clinical Improvement in Deep Brain Stimulation from Intraoperative Microelectrode Recording". *IEEE Transactions on Biomedical Engineering* 64.5 (2017): 1123-1130.

25. Sang Jin Kim., *et al*. "Effects of Subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease". *Neurology* 85 (2015): 425-432.

26. Bour LJ., *et al*. "Long term experience with intraoperative microrecording during DBS neurosurgery in STN and Gpi". *Acta Neurochirurgica* 152.12 (2010): 2069-2077.

27. Zuan He. "Neural Signal processing of microelectrode recordings for deep brain stimulation". *Chalmers University of Technology* (2009).

28. AL Benabid. "Deep brain stimulation for Parkinson's disease". *Current Opinion in Neurobiology* 13.6 (2003): 696-706.

29. AL Benabid., *et al*. "Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease". *Stereotactic and Functional Neurosurgery* 62.1-4 (1994): 76-84.

30. A Moran., *et al*. "Subthalamic nucleus functional organization revealed by Parkinsonian neuronal oscillations and synchrony". *Brain* 131.12 (2008): 3395-3409.

31. GL Defer. "Core assessment program for surgical intervention therapies in Parkinson's disease". *Movement Disorders* 14.4 (1999): 572-584.

32. Andrade-Souza YM., *et al*. "Comparison of three methods of targeting the subthalamic nucleus for chronic stimulation in Parkinson's disease". *Neurosurgery* 62.2 (2008): 875-883.

33. Larry Squire., *et al*. "Fundamental Neuroscience, 4th Edition". AP Academic Press (2012).

34. McClelland S. "A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease". *Movement Disorders* (2011).

35. William H Press., *et al*. "Numerical Recipes in C++, Cambridge University Press" (2002).

36. Andrzej Dobrowolski., *et al*. "Spectral Analysis of Motor Unit Action Potentials". *IEEE Transactions on Biomedical Engineering* 54.12 (2007): 2300-2302.

37. Sabato Santaniello., *et al*. "Therapeutic mechanisms of high-frequency stimulation in Parkinson`s disease and neural restoration via loop-based reinforcement". *Proceedings of the National Academy of Sciences* (2015): 1-10.

38. Sridevi V Sarma., *et al*. "Using point process models to compare neural spiking activity in the subthalamic nucleus of

Parkinson`s patients and a healthy primate". *IEEE Transactions on Biomedical Engineering* 57.6 1297-1305.

39. Hans S., *et al*. "Electrical stimulation inhibits cytosine arabinoside-induce neuronal death by preventing apoptosis in dorsal root ganglion neurons". *NeuroReport* 27.16 (2016): 1217-1224.

40. V Rama Raju., *et al*. "Latent Variate Factorial Principal Component Analysis of Microelectrode Recording of Subthalamic Nuclei Neural Signals with Deep Brain Stimulator in Parkinson Diseaseet.al. Springer Briefs in Forensic and Medical Bioinformatics". *Soft Computing and Medical Bioinformatics* (2018).

41. V Rama Raju. "Principal component latent variate factorial analysis of MER signals of STN-DBS in Parkinson`s disease (Electrode Implantation)". Springer Nature 68.3 (2018).

42. V Rama Raju., *et al*. "The Role of Microelectrode Recording (MER) in STN DBS Electrode Implantation", IFMBE Proceedings, Springer, Vol. 51". *World Congress on Medical Physics and Biomedical Engineering* (2015): 1204-1208.

43. http://www.laskerfoundation.org/awards/2014_c_description.htm